key: cord-0723223-f3lvdl67
authors: Vitner, Einat.B.; Achdout, Hagit; Avraham, Roy; Politi, Boaz; Cherry, Lilach; Tamir, Hadas; Yahalom-Ronen, Yfat; Paran, Nir; Melamed, Sharon; Erez, Noam; Israely, Tomer
title: Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and Influenza virus
date: 2021-02-25
journal: J Biol Chem
DOI: 10.1016/j.jbc.2021.100470
sha: ebc370d96cf44e63e443d9476f013772e3e2b1e3
doc_id: 723223
cord_uid: f3lvdl67

The ongoing COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major threat to global health. Vaccines are ideal solutions to prevent infection, but treatments are also needed for those who have contracted the virus to limit negative outcomes, when vaccines are not applicable. Viruses must cross host cell membranes during their lifecycle, creating a dependency on processes involving membrane dynamics. Thus, in this study we examined whether the synthetic machinery for glycosphingolipids, biologically active components of cell membranes, can serve as a therapeutic target to combat SARS-CoV-2. We examined the antiviral effect of two specific inhibitors of glucosylceramide synthase (GCS); (i) Genz-123346, an analogue of the FDA-approved drug Cerdelga®, and (ii) GENZ-667161, an analogue of venglustat which is currently under phase III clinical trials. We found that both GCS inhibitors inhibit replication of SARS-CoV-2. Moreover, these inhibitors also disrupt replication of influenza virus A/PR/8/34 (H1N1). Our data imply that synthesis of glycosphingolipids is necessary to support viral life cycles, and suggest that GCS inhibitors should be further explored as antiviral therapies.

The recent spread of the novel coronavirus, SARS-CoV-2 has created a worldwide public health emergency. In December 2019, the outbreak of this emerging disease (COVID-19) began in Wuhan, China and rapidly spread. It was declared as pandemic by the World Health Organization in March 2020 (1) . Antiviral drugs which inhibit the replication of SARS-CoV-2 can be used widely to treat patients post infection. Historically, antiviral drug research has mainly focused on targeting viral components, due to the perceived specificity of such an approach (2) . Thus, it is not surprising that, the first drug to be approved against SARS-CoV-2, Remdesivir (also GS-5734), is a directacting antiviral that inhibits the viral RNAdependent RNA polymerase (RdRp) (3) . However, since viral life cycle is dependent on the host, specific host mechanisms can also be explored as antiviral targets. Sphingolipids (SLs) are biologically active components of cell membranes and as such are tightly linked to all processes involving membrane dynamics, making them potential key regulators in the life cycle of obligatory intracellular pathogens such as viruses. Glucosylceramide (GlcCer) is the backbone of more than 300 structurally different Glycosphingolipids (GSLs) including gangliosides and sulfatides. Its accumulation leads to Gaucher diseases accompanied by chronic brain inflammation and activation of the antiviral immune response (4) . Viral-induced elevation of SL levels was shown to be associated with a number of viruses; elevation of GM2-ganglioside and Lactosylceramide was shown upon infection with Zika virus (ZIKV) and Hepatitis C virus (HCV), respectively (5, 6) . Human Cytomegalovirus (HCMV) induces elevation of ceramide and GM2-ganglioside (7) , and Dengue virus (DENV) induces elevation of ceramide and sphingomyelin (8) . Additionally, Influenza virus was shown to induce Sphingomyelin and GlcCer elevation (9, 10) and suppression of the biosynthesis of cellular sphingolipids results in the inhibition of the maturation of influenza virus particles in vitro (11, 12) . Drugs targeting SL metabolizing enzymes are currently in use and constantly being developed for treating Lysosomal storage diseases (LSDs) and other disorders in which alteration in SL levels are involved in disease pathology (13) (14) (15) . This allows a potential repurposing of these already approved drugs as antivirals. In this study, we examined the antiviral activity of two specific inhibitors of UDPglucose:ceramide glucosyltransferase (glucosylceramide synthase (GCS)), (EC 2.4.1.80), which catalyze the biosynthesis of GlcCer. These inhibitors block the conversion of ceramide to GlcCer, the first step in the biosynthesis of gangliosides and other glycosphingolipids.

The following GCS inhibitors were examined: (i) (1R,2R)-nonanoic acid[2-(2′,3′-dihydro-benzo [1, 4] dioxin-6′-yl)-2-hydroxy-1-pyrrolidin-1ylmethyl-ethyl]-amide-l-tartaric acid salt (Genz-123346) termed herein after GZ-346. GZ-346 is an analogue of the FDA-approved drug eliglustat (Cerdelga®) which is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) (16) . (ii) (S)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2yl)carbamate (GENZ-667161) termed herein after GZ-161. GZ-161 is a specific inhibitor of glucosylceramide synthase (GCS) that can access the central nervous system (CNS) and has been demonstrated to effectively reduce glycosphingolipid synthesis (17) (18) (19) . GZ-161 is an analogue of venglustat which is currently under clinical trials for the LSDs; Gaucher's disease, Fabry disease, and Tay-Sachs disease, and is in a Phase 3 pivotal trial for autosomaldominant polycystic kidney disease (17) (18) (19) .

Thus, the antiviral activity of GCS inhibitors was examined for SARS-CoV-2.

To test for antiviral activity of GCS inhibitors against SARS-CoV-2, Vero E6 cells were incubated with 10 μM GZ-161 or GZ-346 one hour prior to infection with SARS-CoV-2 (MOI=0.01). Supernatants were harvested 24 hours post infection (hpi) and analyzed by plaque forming units (PFU) assay to measure the effect of the drugs on SARS-CoV-2 replication ( Figure 1A and B). ~ 1.7e7±1.3e6 PFU/ml were detected in the medium of vehicle DMSO (untreated) infected cells, while only 37 ± 23 and 700 ± 339 PFU/ml were detected in GZ-161 and GZ-346 treated cells, respectively, indicating significant inhibition of virus release (P < 0.0001, P<0.001, respectively). In addition, the ability of GZ-161 and GZ-346 to inhibit single-cycle infection was studied. Vero E6 were infected at high MOI (MOI=5) and viral release was determined at 10 (hpi), an early time point of viral release (20, 21) . GZ-161 and GZ-346 reduced viral release by 70% and 76% respectively, even when SARS-CoV-2 were infected with a high MOI ( Figure 1C ), albeit to a lesser extent compared to low MOI. To further determine the antiviral activity and cell cytotoxicity of GZ-161 and GZ-346 against SARS-CoV-2 infection, we measured their half- To demonstrate that inhibition of GCS directly reduces viral replication, Ugcg (the gene encoding for GCS) was knocked-down by Dicer substrate small interfering RNA (DsiRNA). The resulting ~90% reduction in Ugcg mRNA expression levels 24 h post-transfection ( Figure 3A ) was sufficient to reduce viral release to the medium by 50% ( Figure 3B ), The fact that knocking down Ugcg inhibits SARS-CoV-2 virus, together with that viral inhibition is observed with two GCS inhibitors with different structures (GZ-161, GZ-346) increases the possibility that the antiviral effect of the two compounds is due to GCS inhibition rather than an off-target effect.

Next, the ability of GCS inhibitors to reduce the cytopathic effect (CPE) of SARS-CoV-2 infected cells was examined. Vero E6 cells were incubated with 10 μM GZ-161, or GZ-346, one hour prior to infection with SARS-CoV-2 and cell cytotoxicity was measured at 48 hpi. Treatment with GZ-161 or with GZ-346, one hour before infection, completely eliminated SARS-CoV-2-induced cell cytotoxicity (Fig. 4A ). Taken together, these results demonstrate that GZ-161 and GZ-346 have an antiviral effect on the SARS-CoV-2 clinical isolate in vitro, with a single dose able to significantly inhibit viral replication within 24-48 h.

To determine which stage of SARS-CoV-2 infection cycle was affected by GCS inhibitors, a time-of-addition assay was performed. As shown in Fig 4A- C, inhibition was most effective when GCS inhibitors were added one hour before infection and was not effective when given 1 hpi (Fig. 4C ). When GCS inhibitors were added immediately after SARS-CoV-2-attachment (0 hpi), viral replication was significantly reduced by ~50% (Fig. 4B) . The time-dependence of the inhibitory effect of the compound suggests that its anti-SARS-CoV-2 activity may be due to inhibition of early steps in the SARS-CoV-2 replication cycle. To further examine the stage which is being interrupted by GCS inhibitors in the life cycle of SARS-CoV-2, Vero E6 were infected with high MOI of 5 to ensure singlecycle infection. Cells were incubated with 10 μM GZ-161 or GZ-346 one hour prior to infection with SARS-CoV-2. 5 hpi SARS-CoV-2 nucleocapsid (N) levels were determined ( Fig  4D) . GZ-161 and GZ-346 significantly reduced the levels of N protein in infected cells. Thus, our data suggest that GCS inhibitors inhibit SARS-CoV-2 infection cycle after attachment of the virus and before the translation of sub-genomic proteins.

It was recently shown that Ugcg knockout cells demonstrate a reduction in the replication of the respiratory RNA virus Influenza A virus, a member of the family Orthomyxoviridae (22) . Thus, we further examined the antiviral activity of GCS inhibitors against Influenza A virus. MDCK cells were incubated with 10 μM GZ-161 or GZ-346 one hour prior to infection with mouse adapted influenza virus A/PR/8/34 (H1N1) (PR8). Supernatant was harvested 8 hpi and analyzed by qPCR for the detection of viral RNA in the culture media ( Fig 5A) . A ~90% reduction in viral RNA was measured in samples treated with GZ-161 or GZ-346 compared to the vehicle DMSO (untreated). In addition to their ability to inhibit PR8 replication, the ability of GCS inhibitors to reduce the CPE of PR8 infected cell was further examined. MDCK cells were incubated with 10 μM GZ-161 or GZ-346 one hour prior to infection with PR8 (MOI, 0.1) and LDH release to the supernatant was measured at 24 hpi as an indication for cell disintegration. Both GZ-161 and GZ-346 significantly reduced PR8-induced cytotoxicity by 65% and 90% respectively (Fig.  5B ).

In this study we demonstrate that the GCS inhibitors GZ-161 and GZ-346 inhibit viral replication of SARS-CoV-2. The importance of glycosphingolipids biosynthesis in viral life cycle was demonstrated recently for Influenza virus and severe fever with thrombocytopenia syndrome virus (SFTSV) (22, 23) . Moreover, iminosugars are known for their broad-spectrum antiviral activity, presumably due to their mechanism of action as endoplasmic reticulum (ER)-resident αglucosidases I and II inhibitors (24). 1-Deoxynojirimycin (DNJ) iminosugar derivatives inhibit in vitro production of infectious viruses including dengue virus (DENV) (25, 26) , hepatitis B virus (HBV) (27, 28) , hepatitis C virus (HCV) (29), human immunodeficiency virus (HIV) (30, 31) , and influenza A virus (32) . Antiviral efficacy of the iminosugar N-butyl-DNJ (NB-DNJ, Miglustat, Zavesca) has been further demonstrated in vivo against DENV infection (33) . Although these reports present strong circumstantial evidence that inhibition of ER αglucosidase activity is the cause of iminosugar antiviral activity (34) , the ubiquity of D-glucose in metabolism suggests that other pathways may be equally affected by iminosugar treatment. Indeed, NB-DNJ has been approved for clinical use since 2002 as a second line treatment for Gaucher's disease (35) -an LSD. In this context, NB-DNJ is used as an inhibitor of GCS, to reduce production of GSLs that accumulate due to a deficiency in GlcCer degradation (36) . Thus, the broad antiviral activity of NB-DNJ can also be explained by its inhibition of GCS, suggesting the GSL synthetic pathways may be therapeutic targets for a broad-range of viral infection. Unlike the iminosugar NB-DNJ, eliglustat is a ceramide analogue that inhibits UDP-glucosylceramide synthase without inhibiting of intestinal glycosidases (lactase, maltase, sucrase), α-glucosidase I and II, as was evaluated in in-vitro cell-based and cell-free assays (37, 38) .

The mechanism by which GCS inhibitors block viral replication is not fully-resolved. Sphingolipids play a significant role in endocytosis and thus may play a major role in virus penetration to the cell. Previous works showed that knocking out Ugcg impaired the entry of Influenza virus and SFTSV by endocytosis (22, 23) . This is consistent with our data showing interruption of early stages of SARS-CoV-2 replication. Whether the same mechanism of inhibition is relevant to SARS-CoV-2 needs to be elucidated. Moreover, whether the anti-viral effect of GCS inhibitors is due to decreased levels of glucosylceramide and/or other glycosphingolipids, or due to elevated levels of ceramide needs to be further explored. The antiviral effect of GCS inhibitors on viruses of three different families (i.e; Bunyaviridae, Orthomyxoviridae, and Coronaviridae) suggests a key role of the glycosphingolipid synthesis pathway in viral infection. One advantage of targeting host proteins utilized by multiple viruses over targeting specific viral proteins is it being less prone to the development of resistance to the drug through mutations. While side effects may be of particular concern for such treatments, another advantage of targeting host protein is the availability of many approved drugs against host proteins, allowing for drug repurposing. The main advantage of repurposing approved drugs is that they have already proven to be sufficiently safe, they have successfully passed clinical trials and regulatory scrutiny, and they have already undergone post-marketing surveillance (39) . While the inhibitor NB-DNJ affects multiple host targets, specific inhibition of GCS is now possible using GCS inhibitors which are currently available. Eliglustat is an oral therapy approved in the European Union (2015) and the United States (2014) as a first-line treatment for adults with type 1 Gaucher disease who have compatible CYP2D6 metabolism phenotypes. Phase I studies in healthy volunteers revealed limited toxicity with an excellent pharmacodynamic response (38). A Phase 3 trial in which patients received eliglustat daily (50 or 100 mg twice daily) for 9 months showed mild or moderate adverse events (40, 41) .

We have shown that commercially available, FDA-approved analogues, pharmacological inhibitors specific for GCS have an anti-viral activity against both SARS-CoV-2 and Influenza virus. We suggest that examining the effects of these drugs in-vivo, as well as against other viruses can be beneficial and yield novel treatments for viral infection.

Mandelboim (Tel-Aviv University, Israel). Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heatinactivated fetal calf serum (FCS), Non-essential amino acids (NEAA), 2 mM L-glutamine, 100 units/ml penicillin, 100 μg/ml streptomycin, and 1.25 units/ml nystatin at 37°C under a 5% CO 2 /95% air atmosphere.

(GISAID accession EPI_ISL_406862) was kindly provided by Bundeswehr Institute of Microbiology, Munich, Germany. Stocks were prepared by infection of Vero E6 cells for two days, a time point in which CPE becomes visible. Media were collected and clarified by centrifugation prior to being aliquoted for storage at −80°C. Titer of stock was determined by plaque assay on Vero E6 cells monolayers. Influenza virus A/Puerto Rico/8/34 H1N1 (PR8) was kindly provided by Michal Mandelboim (Tel-Aviv University, Israel).

The compounds GZ-161 ((S)-quinuclidin-3-yl (2- 

Vero E6 cells were seeded at a density of 1.5 × 10 5 cells per well in 24-well plates. Following overnight incubation, cells were treated in 4replicates with GZ-161 or GZ-346. Cells were infected 1 hour later with SARS-CoV-2 (MOI, 0.01 or 5, as indicated). Supernatant was collected 24 hpi or 10 hpi for qPCR and for plaque-forming units (PFU) quantification. For PFU quantification, Vero E6 cells were seeded at a density of 4 × 10 5 cells per well in 12-well plates. Following overnight incubation, cell monolayers were infected with serial dilution of media and 30-35 plaque-forming units (PFU/well) of live virus served as control, and incubated for 48 h at 37 °C. Then, the inhibitory capacity of GCS inhibitors was assessed by determining the numbers of plaques compared with untreated cells. Cells viability were determined 48 hpi by Cell Proliferation Kit (XTT based) (Biological Industries, 20-300-1000) according to manufacturer's protocol. Percentage of inhibition was calculated by subtracting the ratio of PFU between treated and untreated cells from 1. All experiments involving SARS-CoV-2 were conducted in a BSL3 facility in accordance with the IIBR regulation.

Vero E6 cells were seeded at a density of 1.5 × 10 5 cells/well in 24-well plate and allowed to attach overnight in growth medium. For DsiRNA knockdown of Ugcg, cells were transfected with 20 nM of non-targeted or Ugcg-specific DsiRNA (IDT) using Lipofectamine® RNAiMAX reagent (Invitrogen) at 37 °C. The transfection was performed according to the manufacturer's instructions using 1.5 μl Lipofectamine®RNAiMAX in a total volume of 500 µl growth medium without antibiotics. Cells were allowed to grow for 1 d at 37 °C, 5% CO 2 and were then analyzed for Ugcg mRNA expression or infected with SARS-CoV-2. Mocktransfected cells were used as control.

Cells death were determined by CytoTox-Fluor™ Cytotoxicity Assay (Promega, G9262) according to manufacturer's protocol.

Cells were washed twice with PBS and lysed in RIPA buffer (Merck, R0278) supplemented with protease inhibitor cocktail (Merck, P8340). Samples were sonicated twice for 5 seconds to fragment DNA and boiled for 5 minutes to denaturate proteins. Lysates were resolved on 12% SDS-PAGE (Genscript, ExpressPlus™ PAGE Gel, M01212) and subsequently transferred onto a nitrocellulose membrane (ThermoFisher, iBlot™ 2 Transfer Stacks, nitrocellulose, IB23002). The membrane was blocked with 5% bovine serum albumin (Biological industries, 03-010-1B) in PBS-0.05% Tween20 and incubated overnight with primary antibody at 4 °C. After washing, the J o u r n a l P r e -p r o o f membrane was incubated with IRDye 800CW goat anti-rabbit secondary antibody (LI-COR, 926-32211) for 1 h at 20 °C. The membrane was washed with PBS-0.05% Tween and developed using Odyssey ® -CLx imaging system (LI-COR). Primary antibodies include rabbit anti-β-actin (Abcam, AB8227) and Rabbit anti-SARS-CoV-2 nucleocapsid (1:2000, kindly provided by Amir Ben-Shmuel, IIBR, Israel).

MDCK cells were seeded at a density of 5 × 10 5 cells per well in 6-well plates. Following overnight incubation, cells were treated in fourreplicates with GZ-161 or GZ-346. One hour later, cells were infected in serum-free medium containing 0.5 μg/mL TPCK-trypsin with PR8 at MOI 0.1. Supernatants were collected 8 hpi for qPCR. Cell cytotoxicity was determined 24 hpi by LDH Assay (Cytotoxicity) (ab65393) according to manufacturer's protocol. Percentage of inhibition was calculated by subtracting the ratio of PFU between treated and untreated cells from 1.

Statistical analyses were performed with a twotailed unpaired t-test, or one-way ANOVA test followed by Tukey's multiple comparison tests, as indicated in the legends. P values are indicated by asterisks in the figures as follows: *P<0.05, **P<0.01, ***P<0.001, and ****P<0.0001. Differences with a P value of 0.05 or less were considered significant. The exact value of n, is indicted in the figure legends. Data for all measurements are expressed as means ± SEM. Analyses were performed using GraphPad Prism software version 6.0.

All data required for the conclusions made here are contained within the manuscript. Any other data is available at request from the authors. Figure 1 . Inhibition of SARS-CoV-2 by GCS inhibitors. A-B, Vero E6 cells were treated with GZ-161 or with GZ-346 (10µM). One hour later, cells were infected with SARS-CoV-2 diluted in Dulbecco′s Modified Eagle′s medium (MOI, 0.01). 24 hpi viral release to the media was measured by plaque forming units (PFU) assay. Data are means of four replicates ± SEM. *** p <0.001, **** p <0.0001. A representative image of PFU assay is presented in (B). C, Vero E6 cells were treated with GZ-161 or with GZ-346 (10µM). One hour later, cells were infected with SARS-CoV-2 diluted in Dulbecco′s Modified Eagle′s medium (MOI, 5). 10 hpi viral release to the media was measured by PFU assay. Data are means of four replicates ± SEM. ** p <0.01, *** p <0.001. 

World Health Organization. WHO coronavirus disease (COVID-19) dashboard

Antivirals and antiviral strategies

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Induction of the type I interferon response in neurological forms of Gaucher disease

Dynamic remodeling of lipids coincides with dengue virus replication in the midgut of Aedes aegypti mosquitoes

Modulation of Hepatitis C Virus Genome Replication by Glycosphingolipids and Four-Phosphate Adaptor Protein 2

Cytomegalovirus Restructures Lipid Rafts via a US28/CDC42-Mediated Pathway

A Lipidomics Approach in the Characterization of Zika-Infected Mosquito Cells: Potential Targets for Breaking the Transmission Cycle

Lipidomics identifies a requirement for peroxisomal function during influenza virus replication

Influenza virus infection augments NK cell inhibition through reorganization of major histocompatibility complex class I proteins

Suppression of the biosynthesis of cellular sphingolipids results in the inhibition of the maturation of influenza virus particles in MDCK cells

Glucosylceramidase Maintains Influenza Virus Infection by Regulating Endocytosis

Modulation of Neuroinflammation in the Central J o u r n a l P r e -p r o o f Nervous System: Role of Chemokines and Sphingolipids

Sphingolipid lysosomal storage disorders

Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders

Inhibiting Glycosphingolipid Synthesis Improves Glycemic Control and Insulin Sensitivity in Animal Models of Type 2 Diabetes

Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of

Glucosylceramide Synthase for Fabry Disease

CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease

Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease

SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network

SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology

Glucosylceramide synthase maintains influenza virus entry and infection

A role for glycolipid biosynthesis in severe fever with thrombocytopenia syndrome virus entry

Targeting a host process as an antiviral approach against dengue virus

Alpha-glucosidase inhibitors reduce dengue virus production by affecting the initial steps of virion morphogenesis in the endoplasmic reticulum

Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection

Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion

Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications

Inhibitors of endoplasmic reticulum alpha-glucosidases potently virion assembly and release

N-Butyldeoxynojirimycin is a broadly effective anti-HIV therapy significantly enhanced by targeted liposome delivery

Nbutyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure

Strain-specific antiviral activity of iminosugars against human influenza A viruses

Liposome-mediated delivery of iminosugars enhances efficacy against dengue virus in vivo

Iminosugars Inhibit Dengue Virus Production via Inhibition of ER Alpha-Glucosidases--Not Glycolipid Processing Enzymes

Nbutyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis

Neuronal forms of Gaucher disease

A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease

ELIGLUSTAT TARTRATE: Glucosylceramide Synthase Inhibitor Treatment of Type 1 Gaucher Disease

Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics

Effect of Oral Eliglustat on Splenomegaly in Patients With Gaucher Disease Type 1: The ENGAGE Randomized Clinical Trial

Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe

We thank Shay Weiss for Bio-safety advisory and support. We thank Pablo Sardi from Sanofi for providing GZ-161 and GZ-346. We thank Amir Ben-Shmuel for providing the anti-SARS-CoV-2 nucleocapsid antibody and Michal Mandelboim for MDCK cells and Influenza virus A/Puerto Rico/8/34 H1N1 (PR8).